Show simple item record

dc.contributor.authorOmwandho, C A
dc.contributor.authorTinneberg, H R
dc.contributor.authorTumbo-Oeri, A G
dc.contributor.authorRoberts, T K
dc.contributor.authorFalconer, J
dc.date.accessioned2013-06-10T06:56:08Z
dc.date.available2013-06-10T06:56:08Z
dc.date.issued2000
dc.identifier.citationArch Gynecol Obstet. 2000 Jul;264(1):3-12en
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/pubmed/10985611
dc.identifier.urihttp://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/30392
dc.description.abstractPost implantation pregnancy losses are psychologically and economically stressful to the childbearing population. The etiology in the vast majority of cases is unknown but is partly thought to result from a break-down of the maternal tolerance to the fetoplacental unit. Immunologically based therapy remains controversial but no alternative therapy is available at the moment. This article reviews the conceived immunological basis of recurrent pregnancy losses, discussing the controversies arising, and recommending the use of intravenous immunoglobulin, IVIg, in well controlled experiments for further clinical trials.en
dc.titleRecurrent pregnancy losses and the role of immunotherapyen
dc.typeArticleen
local.publisherDepartment of Biochemistry, University of Nairobien


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record